{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:14:13Z","timestamp":1794960853191,"version":"4.9.1"},"reference-count":33,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UCB Pharma"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,6,23]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of lacosamide (up to 12\u2009mg\/kg\/day or 400\u2009mg\/day) as adjunctive treatment for uncontrolled primary generalised tonic-clonic seizures (PGTCS) in patients (\u22654 years) with idiopathic generalised epilepsy (IGE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Phase 3, double-blind, randomised, placebo-controlled trial (SP0982;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02408523\">NCT02408523<\/jats:ext-link>\n                      ) in patients with IGE and PGTCS taking 1\u20133 concomitant antiepileptic drugs. Primary outcome was time to second PGTCS during 24-week treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>242 patients were randomised and received \u22651\u2009dose of trial medication (lacosamide\/placebo: n=121\/n=121). Patients (mean age: 27.7 years; 58.7% female) had a history of generalised-onset seizures (tonic-clonic 99.6%; myoclonic 38.8%; absence 37.2%). Median treatment duration with lacosamide\/placebo was 143\/65 days. Risk of developing a second PGTCS during 24-week treatment was significantly lower with lacosamide than placebo (Kaplan-Meier survival estimates 55.27%\/33.37%; HR 0.540, 95% CI 0.377 to 0.774; p&lt;0.001; n=118\/n=121). Median time to second PGTCS could not be estimated for lacosamide (&gt;50% of patients did not experience a second PGTCS) and was 77.0 days for placebo. Kaplan-Meier estimated freedom from PGTCS at end of the 24-week treatment period (day 166) for lacosamide\/placebo was 31.3%\/17.2% (difference 14.1%; p=0.011). More patients on lacosamide than placebo had \u226550% (68.1%\/46.3%) or \u226575% (57.1%\/36.4%) reduction from baseline in PGTCS frequency\/28 days, or observed freedom from PGTCS during treatment (27.5%\/13.2%) (n=119\/n=121). 96\/121 (79.3%) patients on lacosamide had treatment-emergent adverse events (placebo 79\/121 (65.3%)), most commonly dizziness (23.1%), somnolence (16.5%), headache (14.0%). No patients died during the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lacosamide was efficacious and generally safe as adjunctive treatment for uncontrolled PGTCS in patients with IGE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2020-323524","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T08:45:19Z","timestamp":1597740319000},"page":"1067-1075","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial"],"prefix":"10.1136","volume":"91","clinical-trial-number":[{"clinical-trial-number":"nct02408523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01118949","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01118962","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02408523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02408523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02408549","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David G","family":"Vossler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Knake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steiniger-Brach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Roebling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2024111108050920000_91.10.1067.1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.2.192"},{"key":"2024111108050920000_91.10.1067.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb06073.x"},{"key":"2024111108050920000_91.10.1067.3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/NDT.S209084","article-title":"Status epilepticus in patients with genetic (idiopathic) generalized epilepsy","volume":"15","author":"Bosak","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2024111108050920000_91.10.1067.4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2011.10.009","article-title":"Physical injuries in patients with epilepsy and their associated risk factors","volume":"21","author":"Asadi-Pooya","year":"2012","journal-title":"Seizure"},{"key":"2024111108050920000_91.10.1067.5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1528-1167.2011.03354.x","article-title":"Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis","volume":"53","author":"Hesdorffer","year":"2012","journal-title":"Epilepsia"},{"key":"2024111108050920000_91.10.1067.6","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","article-title":"Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"88","author":"Harden","year":"2017","journal-title":"Neurology"},{"key":"2024111108050920000_91.10.1067.7","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00473","article-title":"Ranking the leading risk factors for sudden unexpected death in epilepsy","volume":"8","author":"DeGiorgio","year":"2017","journal-title":"Front Neurol"},{"key":"2024111108050920000_91.10.1067.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01268.x"},{"key":"2024111108050920000_91.10.1067.9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl047"},{"key":"2024111108050920000_91.10.1067.10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2009.02233.x","article-title":"Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy)","volume":"50 Suppl 8","author":"Somerville","year":"2009","journal-title":"Epilepsia"},{"key":"2024111108050920000_91.10.1067.11","unstructured":"Vimpat . Vimpat\u00ae (lacosamide) Summary of Product Characteristics, 2020. Available: https:\/\/www.ema.europa.eu\/documents\/product-information\/vimpat-epar-product-information_en.pdf [Accessed 29 Jul 2020]."},{"key":"2024111108050920000_91.10.1067.12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension","volume":"130","author":"Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"key":"2024111108050920000_91.10.1067.13","first-page":"77","article-title":"Time to Nth seizure analysis of lamotrigine as adjunctive therapy in subjects with primary generalized tonic-clonic seizures","volume":"48(S6)(abstract 1.211)","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"2024111108050920000_91.10.1067.14","article-title":"Rationale and study design for a novel phase 3, randomized, double-blind trial of adjunctive lacosamide in patients with idiopathic generalized (genetic) epilepsy and uncontrolled primary generalized tonic-clonic seizures","volume":"56(S1)","author":"Warnock","year":"2015","journal-title":"Epilepsia"},{"key":"2024111108050920000_91.10.1067.15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B"},{"key":"2024111108050920000_91.10.1067.16","doi-asserted-by":"publisher","DOI":"10.1191\/0962280205sm397oa"},{"key":"2024111108050920000_91.10.1067.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1330"},{"key":"2024111108050920000_91.10.1067.18","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187118.19221.e4"},{"key":"2024111108050920000_91.10.1067.19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0148"},{"key":"2024111108050920000_91.10.1067.20","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"2024111108050920000_91.10.1067.21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.yebeh.2010.07.022","article-title":"Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study","volume":"19","author":"Biton","year":"2010","journal-title":"Epilepsy Behav"},{"key":"2024111108050920000_91.10.1067.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001930"},{"key":"2024111108050920000_91.10.1067.23","unstructured":"Afra P , Strom L , Bainbridge J , et al . Role of lacosamide as adjunctive treatment of adults with primary generalized epilepsy, 2010. Available: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/12753 [Accessed 15 Apr 2020]."},{"key":"2024111108050920000_91.10.1067.24","unstructured":"Arnold S , Beige A . Adjunctive treatment with lacosamide: an option for generalized epilepsy? 2010. Available: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/12800 [Accessed 15 Apr 2020]."},{"key":"2024111108050920000_91.10.1067.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.12.010"},{"key":"2024111108050920000_91.10.1067.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.10.023"},{"key":"2024111108050920000_91.10.1067.27","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816630084"},{"key":"2024111108050920000_91.10.1067.28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ebcr.2017.08.001","article-title":"Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: a clinical and VEEG study","volume":"8","author":"Abarrategui","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"2024111108050920000_91.10.1067.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"key":"2024111108050920000_91.10.1067.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01951.x"},{"key":"2024111108050920000_91.10.1067.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02496.x"},{"key":"2024111108050920000_91.10.1067.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"2024111108050920000_91.10.1067.33","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-323524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:07:30Z","timestamp":1731323250000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-323524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,15]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jnnp-2020-323524"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-323524","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}